←
Forsell Lab58 posts
Forsell Lab avatar

Forsell Lab

@ForsellLab

Research lab @UmeaUniversity, studying B cell and antibody responses to microbial infection.

◷ Joined May 2019▧ 4 Photos and videos
Florian Krammer avatar
⟳ Forsell Lab retweeted
Florian Krammer@florian_krammer·12 Aug 2023

1) I feel this paper by Mattias Forsell's group is often overlooked but shows something very important: Binding antibody to SARS-CoV-2 spike - in the absence of strong neutralizing antibodies to a new variant - predict protection from mortality. thelancet.com/journals/lanep….

Ben Murrell avatar
⟳ Forsell Lab retweeted
Ben Murrell@BenjMurrell·30 Mar 2023

The lab is recruiting! We're at Karolinska, in Stockholm. We're looking for: - a postdoc with a computational/statistical background, with an interest in evolution and/or deep learning - a few `wetlab' roles, including a postdoc ("antibody stuff"), and lab tech/admin folks. 1/n

Post attachment
Forsell Lab avatar
Forsell Lab@ForsellLab·31 Mar 2023

Our new paper demonstrating the feasibility of at-home sampling to provide equal opportunities for serological testing in rural areas. eurosurveillance.org/content…

Forsell Lab avatar
Forsell Lab@ForsellLab·28 Oct 2022

On the 7th of October, our first grad student Andy Dernstedt defended their thesis “Life and death of human B cells in health and disease”. Here, Andy described multiple aspects of the B cell life cycle during infection and vaccination. Congratulations on your degree! 🎓🥳

Post attachment
Klingström lab avatar
⟳ Forsell Lab retweeted
Klingström lab@KlingstromLab·14 Sep 2022

Happy to share our latest publication: Anti-spike mucosal IgA protection against SARS-Cov-2 omicron infection. Fantastic collaboration with Charlotte Thålin @SmedSorensenLab @KimBlom10 and many more! nejm.org/doi/full/10.1056/NE…

Jason McLellan avatar
⟳ Forsell Lab retweeted
Jason McLellan@McLellan_Lab·25 Aug 2022

86% efficacy for the @pfizer RSV prefusion F vaccine in the elderly is extremely good news! Looks like there will be multiple RSV vaccines available soon for this target population. Still looking forward to seeing the data later this year from their maternal vaccine trial.

Pfizer races to beat rivals GSK, J&J, Moderna for slice of $10bn respiratory jab market: will apply for approval of RSV vaccine after reporting its jab is 86% effective at preventing severe disease on.ft.com/3PO5quX

Post attachment
Jason McLellan avatar
⟳ Forsell Lab retweeted
Jason McLellan@McLellan_Lab·10 Jun 2022

Received an email from Rino Rappuoli this morning informing me, @BarneyGrahamMD and Peter Kwong of the positive phase III data for the RSV prefusion F vaccine results in older adults. It's been almost 10 years since we designed the first prefusion RSV F antigen, DS-Cav1. Amazing!

Post attachment
Kartik Chandran avatar
⟳ Forsell Lab retweeted
Kartik Chandran@ChandranLab·16 Mar 2022

Happy to share latest paper at @scienceTM from our Prometheus consortium on broadly neutralizing antibodies against emerging hantaviruses from human convalescent donors. We're especially excited about one particular antibody we've identified. https://t.co/aqCjEcgPCZ 1/10

Jonas Björk avatar
⟳ Forsell Lab retweeted
Jonas Björk@LU_Jonas_Bjork·6 May 2022

Happy to see our latest #Covidvaccination study in @regionskane published in @Eurosurveillanc Main message - booster dose necessary to maintain sufficient protection against severe disease. @KahnFredrik Supported by @lunduniversity @vinnovase @Vetenskapsradet

Rapid communication: #COVID19 #vaccineeffectiveness against severe disease from #SARSCoV2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern 🇸🇪, December 2021 to March 2022 👇🏾 https://t.co/o1KCPS3kJZ #Omicron #ba2variant #Covidvaccination @LU_Jonas_Bjork

Post attachment